Clarifying contradictions: transportability in 17OHP-C trials and preterm birth outcomes using doubly debiased
Arti V Virkud1, Eric Tchetgen Tchetgen1, Enrique F Schisterman1
1Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
None:
Following the Meis et al. trial that identified a benefit of 17-alpha-hydroxyprogesterone caproate (17OHP-C) in reducing the risk of recurrent preterm birth (PTB) (risk difference (RD) -18.6%; 95% CI, -28.2%, -9.2%), a confirmatory trial (PROLONG) identified no benefit of 17OHP-C (RD, 1.2%; 95% CI, -3.0%, 5.3%). The leading hypothesis is that the difference was due to the heterogeneity in PTB risk. We implemented state-of-the-art methods, using doubly debiased machine learning for transportability to investigate whether the conflicting trial results could be explained by measured differences between trial populations. The estimated RD when transporting the effect in Meis to the PROLONG trial population was -18.6% (95% CI, -55.9%, 8.8%) comparing 17OHP-C to placebo. The estimated RD when transporting PROLONG to Meis was 5.2% (95% CI, -17.3%, 18.1%) comparing 17OHP-C to placebo. Transporting from PROLONG to Meis did not recover the protective effect observed in Meis, which we hypothesize is due to a hidden violation of one or more causal assumptions for transportability, such as the presence of unmeasured effect measure modifiers. Transporting from Meis to PROLONG did not recover the null point estimate observed in PROLONG, though the confidence interval was wide. Future studies should explore effect heterogeneity by PTB.
